Asia Pacific Cell Therapy Market Worth $2.9 Billion By 2028

Asia Pacific Cell Therapy Market Growth & Trends

The Asia Pacific cell therapy market size is expected to reach USD 2.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.9% from 2021 to 2028. Rapid advancements in regenerative medicine are anticipated to provide effective solutions for chronic conditions. A substantial number of companies in the growing markets, such as India and South Korea, are striving to capitalize on the untapped opportunities in the market, thereby driving the market.

The growth is greatly benefitted by the fund and regulatory support from government bodies and regulatory agencies. For instance, in August 2020, the government of South Korea passed an Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine to establish a regulatory system for patient safety during quality control and clinical trials, and to strengthen the regulatory support for regenerative medicine development.

The implementation of the act is expected to enhance clinical studies and approvals of regenerative medicine in South Korea. Furthermore, CAR-T and TCR T-cell therapies have already revolutionized hematologic cancer treatment. With the onset of the COVID-19 pandemic, scientists are deciphering its potential against the novel coronavirus. The concept of using T cells against chronic viral infections, such as HIV and hepatitis B, has already been proposed.

Based on the previous research insights, Singapore-based Duke-NUS medical school’s emerging infectious diseases research program demonstrated the utility of these immunotherapies in treating patients with COVID-19 infection. Thus, an increase in research for use of cell therapies for COVID-19 treatment is expected to drive the market in Asian countries. In April 2021, a team of researchers from Japan used induced pluripotent stem cells (iPS) to find drugs that can effectively inhibit the coronavirus and other RNA viruses.

 Request a free sample copy or view report summary: Asia Pacific Cell Therapy Market Report

Asia Pacific Cell Therapy Market Report Highlights

• The research-use segment accounted for the major revenue share in 2020. This can to a substantial investment in research and their clinical translation in Asian countries

• The segment is also driven by the rapid advances in stem cell research which exhibits the potential to effectively address the unmet demand of pharmaceutical and biotech entities, as well as healthcare professionals in disease management

• On the other hand, the clinical use segment is expected to register a significant growth rate during the forecast period owing to the success of CAR-T and other cellular therapies in recent times

• Furthermore, the declining price of stem cell therapy products is anticipated to boost sales in this segment coupled with rising demand for effective alternatives to conventional therapies against various chronic indications

• Based on the therapeutic area, malignancies captured the maximum revenue share in 2020

• This can be owed to relatively more application of cellular therapies in the management of various cancer types such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma

• The autologous therapies segment dominated the 2020 market owing to the approval of autologous CAR-T therapies, improved survival rate post transplantation procedures, and relatively higher adoption rate

• Japan has emerged as the leading Asian market, which can be attributed to its fast growth as a hub for research on regenerative medicine

• On the other hand, Singapore and India are anticipated to witness the fastest growth over the forecast period owing to the presence of improving financing programs to support and advance cell therapy product development in the countries

Asia Pacific Cell Therapy Market Segmentation

Grand View Research has segmented the Asia Pacific cell therapy market on the basis of use-type, therapy type, and country:

Asia Pacific Cell Therapy Use-type Outlook (Revenue, USD Million, 2017 - 2028)

• Clinical-use

  • By Therapeutic Area

    • Malignancies

    • Muscoskeletal disorders

    • Autoimmune disorders

    • Dermatology

    • Others

  • By Cell Type

    • Stem Cell Therapies

      • BM, Blood, & Umbilical Cord-derived Stem Cells/ Mesenchymal Stem Cells

      • Adipose derived cells

      • Others

    • Non-stem Cell Therapies

• Research-use

Asia Pacific Cell Therapy Type Outlook (Revenue, USD Million, 2017 - 2028)

• Allogenic Therapies

• Autologous Therapies

Asia Pacific Cell Therapy Country Outlook (Revenue, USD Million, 2017 - 2028)

• China

• Japan

• India

• Malaysia

• South Korea

• Philippines

• Australia

• Indonesia

• Singapore

List of Key Players of Asia Pacific Cell Therapy Market

• Kolon TissueGene, Inc.

• JCR Pharmaceuticals Co., Ltd.

• Kolon TissueGene, Inc.

• JCR Pharmaceuticals Co., Ltd.

• MEDIPOST

• PHARMICELL Co., Ltd.

• ANTEROGEN. CO., LTD

• Bristol-Myers Squibb Company

• Novartis AG

• Gilead Sciences, Inc.

• Curocell, Inc.

• JW Therapeutics (Shanghai) Co., Ltd.

• Stempeutics Research PVT LTD